Header Logo

Connection

SANJAY MATHEW to Ketamine

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Ketamine.
SANJAY MATHEW
Connection Strength
16.136
Ketamine
  1. Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? JAMA Psychiatry. 2023 12 01; 80(12):1187-1188.
    View in: PubMed
    Score: 0.680
  2. Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604.
    View in: PubMed
    Score: 0.678
  3. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
    View in: PubMed
    Score: 0.652
  4. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
    View in: PubMed
    Score: 0.630
  5. An Update on Community Ketamine Practices. Am J Psychiatry. 2022 05; 179(5):393-394.
    View in: PubMed
    Score: 0.610
  6. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. Expert Opin Drug Saf. 2022 Jun; 21(6):745-759.
    View in: PubMed
    Score: 0.604
  7. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. Ann Clin Psychiatry. 2022 02; 34(1):33-43.
    View in: PubMed
    Score: 0.599
  8. Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
    View in: PubMed
    Score: 0.596
  9. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
    View in: PubMed
    Score: 0.592
  10. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391.
    View in: PubMed
    Score: 0.571
  11. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
    View in: PubMed
    Score: 0.563
  12. Ketamine for depression clinical issues. Adv Pharmacol. 2020; 89:131-162.
    View in: PubMed
    Score: 0.528
  13. Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change. Am J Psychiatry. 2020 02 01; 177(2):107-109.
    View in: PubMed
    Score: 0.522
  14. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 02; 77:19-26.
    View in: PubMed
    Score: 0.483
  15. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015 Oct; 17(10):81.
    View in: PubMed
    Score: 0.386
  16. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs. 2015 Mar; 29(3):181-8.
    View in: PubMed
    Score: 0.371
  17. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43.
    View in: PubMed
    Score: 0.348
  18. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
    View in: PubMed
    Score: 0.336
  19. The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries. CNS Neurosci Ther. 2013 Jun; 19(6):390-5.
    View in: PubMed
    Score: 0.324
  20. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012 Oct 01; 72(7):537-47.
    View in: PubMed
    Score: 0.307
  21. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012 Mar 01; 26(3):189-204.
    View in: PubMed
    Score: 0.301
  22. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 Jan 15; 67(2):139-45.
    View in: PubMed
    Score: 0.260
  23. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009 Sep 01; 66(5):522-6.
    View in: PubMed
    Score: 0.251
  24. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010 Feb; 13(1):71-82.
    View in: PubMed
    Score: 0.245
  25. Glutamate modulators as novel interventions for mood disorders. Braz J Psychiatry. 2005 Sep; 27(3):243-8.
    View in: PubMed
    Score: 0.193
  26. Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression. J Psychopathol Clin Sci. 2025 Apr; 134(3):228-238.
    View in: PubMed
    Score: 0.180
  27. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 06 03; 7(6):e2417786.
    View in: PubMed
    Score: 0.176
  28. Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439.
    View in: PubMed
    Score: 0.176
  29. Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a?randomized controlled trial. EBioMedicine. 2024 Jan; 99:104902.
    View in: PubMed
    Score: 0.171
  30. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply. N Engl J Med. 2023 Sep 07; 389(10):961-962.
    View in: PubMed
    Score: 0.167
  31. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22; 388(25):2315-2325.
    View in: PubMed
    Score: 0.164
  32. Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. Transl Psychiatry. 2023 05 09; 13(1):159.
    View in: PubMed
    Score: 0.164
  33. One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 05 01; 6(5):e2312434.
    View in: PubMed
    Score: 0.163
  34. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 12 12; 84(1).
    View in: PubMed
    Score: 0.159
  35. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1).
    View in: PubMed
    Score: 0.158
  36. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. Int J Neuropsychopharmacol. 2022 10 25; 25(10):827-838.
    View in: PubMed
    Score: 0.158
  37. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968.
    View in: PubMed
    Score: 0.157
  38. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022 12; 27(12):5096-5112.
    View in: PubMed
    Score: 0.156
  39. A Case of Intranasal Ketamine Misuse: Considerations for Clinical Practice. J Psychiatr Pract. 2021 11 05; 27(6):492-495.
    View in: PubMed
    Score: 0.147
  40. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 08; 49:122-132.
    View in: PubMed
    Score: 0.143
  41. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4).
    View in: PubMed
    Score: 0.133
  42. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.133
  43. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.127
  44. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019 11 01; 176(11):923-930.
    View in: PubMed
    Score: 0.125
  45. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019 06; 44(7):1233-1238.
    View in: PubMed
    Score: 0.121
  46. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.121
  47. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.121
  48. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280.
    View in: PubMed
    Score: 0.121
  49. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.119
  50. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 02 01; 175(2):150-158.
    View in: PubMed
    Score: 0.111
  51. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 01; 74(4):399-405.
    View in: PubMed
    Score: 0.107
  52. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486.
    View in: PubMed
    Score: 0.107
  53. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017 Jul; 42(8):1739-1746.
    View in: PubMed
    Score: 0.107
  54. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
    View in: PubMed
    Score: 0.093
  55. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52.
    View in: PubMed
    Score: 0.093
  56. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58.
    View in: PubMed
    Score: 0.092
  57. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5.
    View in: PubMed
    Score: 0.089
  58. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15; 74(4):250-6.
    View in: PubMed
    Score: 0.077
  59. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry. 2011 Mar; 72(3):414-5.
    View in: PubMed
    Score: 0.070
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.